Surgical stapler with integrated bladder

Information

  • Patent Grant
  • 11020578
  • Patent Number
    11,020,578
  • Date Filed
    Thursday, April 7, 2016
    8 years ago
  • Date Issued
    Tuesday, June 1, 2021
    3 years ago
Abstract
An end effector includes first and second members that each have a tissue contacting surface and are moveable relative to one another. The first and second members are configured to clamp tissue therebetween when in an approximated configuration. The tissue contacting surface of the first member defines a first groove. The end effector also includes a bladder that is defined within the first groove and is configured to receive and retain fluid.
Description
BACKGROUND
1. Technical Field

The present disclosure relates to surgical instruments and, more specifically, to surgical instruments with integrated bladders.


2. Discussion of Related Art

Throughout the years the medical field has utilized various techniques in an effort to join or bond body tissue together. Surgical staplers have been developed for joining adjacent tissue, for providing hemostasis of adjacent tissue, and for providing hemostasis in conjunction with cutting of adjacent tissue. Such surgical staplers include both linear and annular type configurations. The intended function of staples is to hold the edges of a wound or tissue against one another during the healing process so as to reduce discomfort, pain, scarring and the time required for healing.


Linear or annular surgical stapling devices are employed by surgeons to sequentially or simultaneously apply one or more rows of surgical fasteners, e.g., staples or two-part fasteners, to body tissue for the purpose of joining segments of body tissue together and/or for the creation of anastomoses. Linear surgical stapling devices generally include a pair of jaws between which body tissue to be joined is placed. When the surgical stapling device is actuated and/or “fired”, firing bars move longitudinally and contact staple drive members in one of the jaws, and surgical staples are pushed through the body tissue and into/against an anvil in the opposite jaw thereby crimping the staples closed. A knife blade may be provided to cut between the rows/lines of staples.


Annular surgical stapling devices generally include an annular staple cartridge assembly including a plurality of annular rows of staples, typically two rows of staples, an anvil assembly operatively associated with the annular cartridge assembly, and an annular blade disposed internal of the rows of staples.


In addition to the use of surgical staples, biological tissue adhesives have been developed for joining tissue. Generally, biological adhesives bond separated tissues together. Such adhesives may be used instead of suturing and stapling, for example, in surgical procedures, for the repair of tissue or the creation of anastomoses.


In addition to the use of biological adhesives, following the formation of the anastomosis, a separate instrument or device may be used to apply biological sealants to the outer surface of the anastomosis, typically in a separate step. The biological sealants are intended to reduce and/or stop the incidence of leakage from the anastomosis.


The application of adhesives and/or sealants offers many advantages to the patient and the surgeon alike, such as, for example, the possible reduction in the number of staples used, immediate sealing of the tissue being treated, a strengthening of the anastomosis, minimizing foreign body reaction and scarring, and a reduction in the occurrence of bleeding from the blood vessels, leakage through the tissue joint, and stricture.


There remains room for improvement in the delivery of fluids, such as adhesives and/or sealants, from surgical stapling instruments.


SUMMARY

Surgical staplers in accordance with this disclosure include end effectors having integrated bladders which dispense fluid (e.g., therapeutic drug, sealant, adhesive, or medicant) when punctured by a fastener during the joining of tissue by the surgical stapler. The bladder may be prefilled with fluid or fluid may be injected into the bladder prior to or during a surgical procedure.


In an aspect of the present disclosure, an end effector includes first and second members that each have a tissue contacting surface and are moveable relative to one another. The first and second members are configured to clamp tissue therebetween when in an approximated configuration. The tissue contacting surface of the first member defines a first groove. The end effector also includes a bladder that is defined within the first groove and is configured to receive and retain fluid.


In aspects, the bladder is configured to receive a fluid when the first and second members are in the approximated position. The bladder may be defined by an inner surface of the first groove and a first film disposed on the tissue contacting surface of the first member.


In some aspects, the end effector includes an injection port that is in fluid communication with the bladder. The injection port may be located on one of the first or second members and is configured to receive fluid from an injection device while the first and second members are in the approximated configuration.


In certain aspects, the first member includes a fastener that is configured to pierce the bladder as the fastener is ejected from the first member. The bladder may be configured to dispense a fluid onto tissue adjacent or proximate to the tissue contacting surface of the first member when the fastener pierces the bladders.


In particular aspects, the tissue contacting surface of the second member defines a second groove. The end effector may include a second bladder defined by an inner surface of the second groove and a second film disposed on the tissue contacting surface of the second member.


In aspects, the end effector is an annular end effector with the first member being a shell assembly and the second member being an anvil assembly. Alternatively, the end effector is a linear end effector with the first member being a lower jaw and the second member being an upper jaw.


In another aspect of the present disclosure, a method of joining tissue includes approximating first and second members of an end effector to clamp tissue to be joined between the first and second members, injecting fluid into a bladder defined in one of the first or second members while the first and second members are clamped on tissue, and ejecting a fastener from the first member such that the fastener pierces the bladder to release fluid from the bladder.


In aspects, ejecting the fastener from the first member includes the fastener piercing the bladder before the fastener passes through the tissue to be joined and coating the fastener with fluid disposed within the bladder. Ejecting the fastener from the first member may include the fastener piercing the bladder after the fastener passes through the tissue to be joined such that the bladder secretes fluid on tissue adjacent a tissue contacting surface of the second member.


In some aspects, injecting fluid into a bladder includes injecting fluid that includes at least one of a therapeutic drug, a biocompatible adhesive, or a biocompatible sealant. Injecting fluid into a bladder may include injecting a first fluid into a bladder that is defined by the first member and injecting a second fluid into a bladder that is defined by the second member. The second fluid may be different from the first fluid.


Further, to the extent consistent, any of the aspects described herein may be used in conjunction with any or all of the other aspects described herein.





BRIEF DESCRIPTION OF THE DRAWINGS

Various aspects of the present disclosure are described hereinbelow with reference to the drawings, which are incorporated in and constitute a part of this specification, wherein:



FIG. 1 is a perspective view of a surgical instrument with a manually actuated handle assembly and a linear stapling end effector in accordance with an exemplary embodiment of the present disclosure;



FIG. 2 is an enlarged view of the indicated area of detail of FIG. 1 with an injection device inserted into an injection port of the end effector;



FIG. 3 is a cross-sectional view taken along the section line 3-3 of FIG. 2;



FIG. 4 is a perspective view of the end effector of FIG. 2 with jaws of the end effector approximated on tissue;



FIG. 5 is a cross-sectional view taken along the second line 5-5 of FIG. 4;



FIG. 6 is a cross-sectional view of the end effector of FIG. 5 with fasteners ejected from the lower jaw to form staples;



FIG. 7 is a perspective view of a surgical instrument with a powered handle and a annular stapling end effector in accordance with another exemplary embodiment of the present disclosure;



FIG. 8 is an enlarged view of the indicated area of detail of FIG. 7 with an injection device inserted into an injection port of the end effector;



FIG. 9 is a cross-sectional view taken along the section line 9-9 of FIG. 8; and



FIG. 10 is a cross-sectional view of the end effector of FIG. 9 with the anvil assembly actuated over tissue and fasteners ejected from the shell assembly towards the anvil assembly.





DETAILED DESCRIPTION

Embodiments of the present disclosure are now described in detail with reference to the drawings in which like reference numerals designate identical or corresponding elements in each of the several views. As used herein, the term “clinician” refers to a doctor, a nurse, or any other care provider and may include support personnel. Throughout this description, the term “proximal” refers to the portion of the device or component thereof that is closest to the clinician and the term “distal” refers to the portion of the device or component thereof that is farthest from the clinician.


This disclosure is generally related to end effectors for surgical staplers including integrated bladders which disperse a fluid (e.g., therapeutic drug, sealant, adhesive, or medicant) when punctured by a fastener to assist in the joining of tissue with the surgical stapler. The bladder may be prefilled with the fluid during manufacture of the instrument or the fluid may be injected into the integrated bladder prior to or during a surgical procedure. The end effector may have an integrated bladder on each side of the tissue with the same or different fluid being dispensed from each integrated bladder. The end effector may be supplied as a part of a loading unit (disposable or reusable) or may be supplied as part of surgical instrument. The end effector may be linear or annular in configuration. In addition, the surgical stapler may be manually actuated, may be actuated by an electromechanical handle, or may be actuated by a pneumatic handle. For example, the pneumatic handle can be a handle powered by a gas cylinder.


Referring now to FIG. 1, a surgical instrument 10 having a manually actuated handle assembly 20 including a linear stapling end effector 50 is provided in accordance with an exemplary embodiment of the present disclosure. The surgical instrument 10 includes the manually actuated handle assembly 20, an elongate portion 30, a loading unit 40, and an end effector 50. The elongate portion 30 extends from the handle assembly 20 and supports the loading unit 40. The loading unit 40 is releasably coupled to the distal end of the elongate portion 30. The end effector 50 is supported at a distal end of the loading unit 40 and includes first and second jaws 52, 56 that are moveable relative to one another. The handle assembly 20 includes a moveable handle 22 that is configured to actuate the end effector 50 to approximate the first and second jaws 52, 56 of the end effector 50 relative to one another and to fire or eject a plurality of fasteners (e.g., staples) through tissue positioned between the first and second jaws 52, 56. For a detailed description of a suitable manually actuated handle assembly and stapling instrument reference may be made to U.S. Pat. No. 8,789,737 (“the '737 Patent”), the entire contents of which is incorporated herein by reference.


With reference to FIGS. 2 and 3, the first or lower jaw or member 52 of the end effector 50 includes a tissue contacting surface 53 that defines longitudinal grooves 54. Each of the grooves 54 includes an inner surface (in embodiments a pair of sidewalls and a bottom surface) and is positioned over a line of fasteners 55. The lower jaw 52 includes an integrated bladder 62 disposed within one or more of the grooves 54. The integrated bladder 62 is formed from an upper film 53a disposed along the tissue contacting surface 53 of the lower jaw 52 and a lower film 53b that is disposed over a bottom surface of the groove 54 such that sidewalls of the groove 54 form sidewalls of the integrated bladder 62. The upper film 53a may be disposed over the entire tissue contacting surface 53 of the lower jaw 52 and secured to the tissue contacting surface 53 between each of the grooves 54. The end effector 50 defines an injection port 66 and includes a delivery tube 63 that extends from the injection port 66, through the lower jaw 52, and to the integrated bladder 62 such that the injection port 66 is in fluid communication with the integrated bladder 62. The integrated bladder 62 may include fingers 62a with each finger 62a extending through a respective groove 54 and a plenum 62b in fluid communication with each finger 62a. The plenum 62b is in fluid communication with the injection port 66 through the delivery tube 63. Alternatively, the integrated bladder 62 may be formed from individual fingers 62a with the delivery tube 63 in fluid communication with each of the individual fingers 62a. The injection port 66 may include an auto-sealing septum to prevent injected fluid from exiting through the injection port 66.


It is also contemplated, that the integrated bladder 62 may be formed from individual fingers 62a with each finger 62a in fluid communication with the injection port 62 through an individual delivery tube 63 such that each individual delivery tube 63 is separately accessible through the injection port 66 to deliver a different fluid to each individual finger 62a. In such an embodiment, the individual fingers 62a may be paired with one or more delivery tubes 63 such that the inner fingers 62a of the integrated bladder 62 (adjacent a knife slot (not explicitly shown)) may be filled with a first fluid and the outer fingers 62a of the integrated bladder 62 (away from a knife slot (not explicitly shown)) may be filed with a second fluid that is different from the first fluid.


Further, it is contemplated that the second or upper jaw or member 56 may define longitudinal grooves 58 in a tissue contacting surface 57 of the upper jaw 56. Each of the grooves 58 is positioned over a line of staple pockets 59 or retainers (not shown). The upper jaw 56 includes an integrated bladder 64 that is disposed within each of the grooves 58 and a delivery tube 65 in fluid communication with the integrated bladder 64. The integrated bladder 64 is formed from a lower film 57a that is disposed along the tissue contacting surface 57 of the upper jaw 56 such that the staple pockets 59 and sidewalls defining the grooves 58 form the integrated bladder 64. The lower film 57a may be disposed over the entire tissue contacting surface of the upper jaw 56 and secured to the tissue contacting surface 57 between each of the grooves 58. The injection port 66 and the delivery tube 65 are also in fluid communication in a manner similar to the integrated bladder 62 and delivery tube 63 of the lower jaw 52. Similarly, the integrated bladder 64 may include fingers 64a with each finger 64a extending through a respective groove 58 and a plenum 64b in fluid communication with each finger 64a. The plenum 64b is in fluid communication with the injection port 66 through the delivery tube 65. Alternatively, the integrated bladder 64 may be formed from individual fingers 64a with the delivery tube 65 in fluid communication with each of the individual fingers 64a. In addition, the end effector 50 may define a second injection port 67 adjacent the injection port 66 which is in fluid communication with the integrated bladder 64. In such embodiments, the integrated bladder 64 of the upper jaw 56 is in fluid communication with the second injection port 67 and the integrated bladder 62 of the lower jaw 52 is in fluid communication with the injection port 66 such that each of the bladders 62, 64 may be individually and separately filled as detailed below. As shown, both injection ports 66, 67 are positioned on the upper jaw 56; however, it is contemplated that one or both of the injection ports 66, 67 may be positioned on the lower jaw 52.


Referring now to FIGS. 2-5, the integrated bladder 62 has an initial or unfilled configuration (FIGS. 2 and 3) and a filled configuration (FIGS. 4 and 5). In the unfilled configuration, the integrated bladder 62 is collapsed such that an upper surface of the integrated bladder 62 is positioned below the tissue contacting surface 53 of the lower jaw 52. In the filled configuration, fluid which is injected through the injection port 66 fills or expands the integrated bladder 62 such that the upper surface of the integrated bladder 62 is coplanar with the tissue contacting surface 53 of the lower jaw 52. In addition, as the integrated bladder 62 is filled through the injection port 66, the integrated bladder 62 may expand to fill any cavities within the grooves 54. It is contemplated that the integrated bladder 62 may include semi-rigid walls such that in the unfilled configuration the upper surface of the integrated bladder 62 is coplanar with the tissue contacting surface 53 of the lower jaw 52.


With particular reference to FIG. 2, an injection device or needle 90 may be inserted into the injection port 66 to inject a fluid into the integrated bladder 62. The fluid may include a therapeutic drug, a biocompatible sealant, a biocompatible adhesive, or a combination thereof. The material can be a bioactive material such as a drug, an immunosuppressant, steroid, entihistimine, etc. Anti-adhesives, antimicrobials, anesthetics, growth factors, or other materials are contemplated.


As the fluid is injected into the integrated bladder 62, the integrated bladder 62 transitions to the filled configuration as detailed above. As the integrated bladder 62 reaches the filled configuration, the pressure of the fluid within the needle 90 may exceed a threshold pressure to indicate that the integrated bladder 62 is in the filled configuration. Additionally or alternatively, as the integrated bladder 62 reaches the filled configuration, the fluid may flow out of the injection port 66 to provide an indication that the integrated bladder 62 is in the filled configuration. It will be appreciated that the fluid may be injected into the integrated bladder 62 before or after the upper and lower jaws 52, 56 are approximated over tissue. To fill the integrated bladder 62 after the upper and lower jaws 52, 56 are approximated over tissue, the fluid may be injected through injection port 68 or 69 (FIG. 1) which may be disposed outside of the body cavity of a patient and connected to bladders 62, 64 via a delivery tube (not explicitly shown).


As detailed above, the unfilled and filled configurations were detailed with respect to the integrated bladder 62 of the lower jaw 52. It will be appreciated that the integrated bladder 64 of the upper jaw 56 has unfilled and filled configurations substantially similar to the integrated bladder 64. As such, the unfilled and filled configurations of the integrated bladder 64 will not be discussed in detail for reasons of brevity.


With reference to FIG. 6, as the fasteners 55 are ejected from the lower jaw 52 towards the upper jaw 56, the fasteners 55 pierce the integrated bladder 62 of the lower jaw 52 such that the fasteners 53 are coated with the fluid disposed within the integrated bladder 62. The coated fasteners 55 then pass through tissue T positioned between the upper and lower jaws 52, 56. After the fasteners 55 pass through the tissue T, the fasteners 55 pierce the integrated bladder 64 of the upper jaw 56 before engaging staple pockets 59 or retainers (not shown) to secure the tissue T together.


When the integrated bladders 62, 64 are pierced, the fluid from the integrated bladders 62, 64 may coat the fasteners 55 and/or the tissue T between the upper and lower jaws 52, 56. The fluid may also flow into openings in the tissue T created by the fasteners 55 to enhance anastomosis, to enhance adhesion, or to seal the tissue T to prevent bleeding of the tissue T.


Referring now to FIG. 7, a surgical instrument 110 having a powered handle 120 including an annular or circular stapling end effector 150 is provided in accordance with another exemplary embodiment of the present disclosure. The surgical instrument 110 includes a powered handle 120, an adapter 130, a loading unit 140, and an end effector 150. The adapter 130 is releasably coupled to the powered handle 120 and extends from the powered handle 120. The loading unit 140 is releasably coupled to a distal end of the adapter 130. The end effector 150 is supported at a distal end of the loading unit 140 and includes a shell assembly 152 and an anvil assembly 156 that are moveable relative to one another. The powered handle 120 is configured to actuate the end effector 150 to approximate the shell and anvil assemblies 152, 156 of the end effector 150 relative to one another and to fire a plurality of fasteners (e.g., staples) through tissue positioned between the shell and anvil assemblies 152, 156. For a detailed description of the structure and function of an exemplary adapter and loading unit, please refer to commonly owned U.S. Provisional Patent Application Ser. No. 62/066,518 filed Oct. 21, 2014. For a detailed description of the structure and function of an exemplary powered handle, please refer to commonly owned U.S. Patent Publication No. 2012/0253329. Each of these applications is incorporated herein by reference in its entirety.


With reference to FIGS. 8 and 9, the first or shell assembly or member 152 has a tissue contacting surface 153 that defines an annular groove 154 with an outer surface of the shell assembly 152. The shell assembly 152 includes an integrated bladder 162 disposed within the annular groove 154 and positioned between a plurality of fasteners 155 and the tissue contacting surface 153. The integrated bladder 162 is defined between an outer film 153a disposed along the tissue contacting surface 153 and an inner film 153b disposed over the plurality of fasteners 155. The shell assembly 152 defines an injection port 166 that is in fluid communication with the integrated bladder 162 via a delivery tube 163.


Additionally or alternatively, the anvil assembly 156 has a tissue contacting surface 157 defines an annular groove 158. The annular groove 158 is positioned between the tissue contacting surface 157 and staple pockets 159 or retainers (not shown) of the anvil assembly 156. The anvil assembly 156 includes an integrated bladder 164 disposed within the annular groove 158. The integrated bladder 164 is defined between an outer film 157a and the staple pockets 159. The distal surface of the anvil assembly 156 may define a second injection port 167 that is in fluid communication with the integrated bladder 164 via a delivery tube 165.


With reference to FIGS. 8-10, the integrated bladders 162, 164 have an unfilled configuration (FIG. 9) and a filled configuration (FIG. 10) which are substantially similar to the unfilled and filled configurations of the integrated bladders 62, 64 detailed above. As shown, the integrated bladders 162, 164 have semi-rigid walls; however, it is contemplated that integrated bladders 162, 164 may have collapsible walls as detailed above with respect to integrated bladders 62, 64.


With reference to FIG. 10 and similar to the integrated bladders 62, 64 as detailed above with respect to the linear end effector 50, the integrated bladders 162, 164 of the circular end effector 150 coat the fasteners 155 and the tissue T as the fasteners 155 are driven through the integrated bladder 162 of the shell assembly 152 to pierce the integrated bladder 162 and to secrete fluid from the integrated bladder 164 of the anvil assembly 156 as the fasteners 155 pierce the integrated bladder 164.


In any of the embodiments disclosed herein, the instrument could have channels for conveying the fluid. In such embodiments, the channels would dispense the fluid whether or not the buttress was present.


While several embodiments of the disclosure have been shown in the drawings, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Any combination of the above embodiments is also envisioned and is within the scope of the appended claims. Therefore, the above description should not be construed as limiting, but merely as exemplifications of particular embodiments. Those skilled in the art will envision other modifications within the scope of the claims appended hereto.

Claims
  • 1. An end effector comprising: first and second members each having a tissue contacting surface, the first and second members movable relative to one another and configured to clamp tissue therebetween in an approximated configuration, the tissue contacting surface of the first member defining a first groove; anda bladder configured to receive and retain fluid, the bladder including a first film disposed along a surface of the first groove of the first member and a second film disposed on the tissue contacting surface of the first member such that sidewalls of the first groove of the first member form sidewalls of the bladder, whereby the fluid received in the bladder is exposed to the sidewalls of the first groove of the first member;wherein in an unfilled state the second film is positioned below the tissue contacting surface of the first member, and in the filled state the second film is coplanar with the tissue contacting surface of the first member.
  • 2. The end effector according to claim 1, wherein the bladder is configured to receive fluid when the first and second members are in the approximated configuration.
  • 3. The end effector according to claim 1, further comprising an injection port in fluid communication with the bladder.
  • 4. The end effector according to claim 3, wherein the injection port is located on one of the first or second members and is configured to receive fluid from an injection device while the first and second members are in the approximated configuration.
  • 5. The end effector according to claim 1, wherein the first member includes a fastener configured to pierce the bladder as the fastener is ejected from the first member.
  • 6. The end effector according to claim 5, wherein the bladder is configured to dispense fluid onto tissue adjacent with the tissue contacting surface of the first member when the fastener pierces the bladder.
  • 7. The end effector according to claim 1, wherein the tissue contacting surface of the second member defines a second groove.
  • 8. The end effector according to claim 7, further comprising a second bladder including a third film disposed along an inner surface of the second groove and a fourth film disposed on the tissue contacting surface of the second member.
  • 9. The end effector according to claim 1, wherein the end effector is an annular end effector, the first member is a shell assembly, and the second member is an anvil assembly.
  • 10. The end effector according to claim 1, wherein the end effector is a linear end effector, the first member is a lower jaw, and the second member is an upper jaw.
  • 11. A method of joining tissue comprising: approximating first and second members of an end effector to clamp tissue to be joined between the first and second members;injecting fluid into a bladder defined in one of the first or second members before or after the first and second members are clamped on tissue, the bladder defined between a first film disposed in a groove of one of the first or second members and a second film on a tissue contacting surface of the same one of the first or second members such that sidewalls of the groove of the one of the first or second members form sidewalls of the bladder, whereby a fluid received in the bladder is exposed to the sidewalls of the groove of the one of the first or second members;wherein in an unfilled state the second film is positioned below the tissue contacting surface of the first member, and in a filled state the second film is coplanar with the tissue contacting surface of the first member; andejecting a fastener from the first member such that the fastener pierces the bladder to release fluid from the bladder.
  • 12. The method according to claim 11, wherein ejecting the fastener from the first member includes the fastener piercing the bladder before the fastener passes through the tissue to be joined and coating the fastener with fluid disposed within the bladder.
  • 13. The method according to claim 11, wherein ejecting the fastener from the first member includes the fastener piercing the bladder after the fastener passes through the tissue to be joined such that the bladder secretes fluid on tissue adjacent a tissue contacting surface of the second member.
  • 14. The method according to claim 11, wherein injecting fluid into a bladder includes injecting fluid that includes at least one of a therapeutic drug, a biocompatible adhesive, or a biocompatible sealant.
  • 15. The method according to claim 11, wherein injecting fluid into a bladder includes injecting a first fluid into a bladder defined by the first member and injecting a second fluid into a bladder defined by the second member.
  • 16. The method according to claim 15, wherein the second fluid is different from the first fluid.
  • 17. The end effector according to claim 1, wherein the first member includes a fastener configured to pierce the first and second films as the fastener is ejected from the first member.
  • 18. The end effector according to claim 17, wherein the fastener pierces the first film prior to piercing the second film.
  • 19. The method according to claim 11, wherein ejecting the fastener from the first member includes the fastener piercing the first film prior to piercing the second film.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of and priority to U.S. Provisional Patent Application Ser. No. 62/148,827 filed Apr. 17, 2015, this application also claims the benefit of and priority to U.S. Provisional Patent Application Ser. No. 62/145,930 filed Apr. 10, 2015, the entire disclosure of which is incorporated by reference herein.

US Referenced Citations (512)
Number Name Date Kind
3054406 Usher Sep 1962 A
3079606 Bobrov et al. Mar 1963 A
3124136 Usher Mar 1964 A
3364200 Ashton et al. Jan 1968 A
3490675 Green et al. Jan 1970 A
3499591 Green Mar 1970 A
3939068 Wendt et al. Feb 1976 A
3948666 Kitanishi et al. Apr 1976 A
4064062 Yurko Dec 1977 A
4166800 Fong Sep 1979 A
4282236 Broom Aug 1981 A
4347847 Usher Sep 1982 A
4354628 Green Oct 1982 A
4416698 McCorsley, III Nov 1983 A
4429695 Green Feb 1984 A
4452245 Usher Jun 1984 A
4605730 Shalaby et al. Aug 1986 A
4626253 Broadnax, Jr. Dec 1986 A
4655221 Devereux Apr 1987 A
4834090 Moore May 1989 A
4838884 Dumican et al. Jun 1989 A
4927640 Dahlinder et al. May 1990 A
4930674 Barak Jun 1990 A
5002551 Linsky et al. Mar 1991 A
5014899 Presty et al. May 1991 A
5040715 Green et al. Aug 1991 A
5057334 Vail Oct 1991 A
5065929 Schulze et al. Nov 1991 A
5162430 Rhee et al. Nov 1992 A
5205459 Brinkerhoff et al. Apr 1993 A
5263629 Trumbull et al. Nov 1993 A
5307976 Olson et al. May 1994 A
5312023 Green et al. May 1994 A
5314471 Brauker et al. May 1994 A
5318221 Green et al. Jun 1994 A
5324775 Rhee et al. Jun 1994 A
5326013 Green et al. Jul 1994 A
5332142 Robinson et al. Jul 1994 A
5344454 Clarke et al. Sep 1994 A
5392979 Green et al. Feb 1995 A
5397324 Carroll et al. Mar 1995 A
5410016 Hubbell et al. Apr 1995 A
5425745 Green et al. Jun 1995 A
5441193 Gravener Aug 1995 A
5441507 Wilk Aug 1995 A
5443198 Viola et al. Aug 1995 A
5468253 Bezwada et al. Nov 1995 A
5484913 Stilwell et al. Jan 1996 A
5503638 Cooper et al. Apr 1996 A
5514379 Weissleder et al. May 1996 A
5542594 McKean et al. Aug 1996 A
5543441 Rhee et al. Aug 1996 A
5549628 Cooper et al. Aug 1996 A
5550187 Rhee et al. Aug 1996 A
5575803 Cooper et al. Nov 1996 A
5653756 Clarke et al. Aug 1997 A
5683809 Freeman et al. Nov 1997 A
5690675 Sawyer et al. Nov 1997 A
5702409 Raybum et al. Dec 1997 A
5752965 Francis et al. May 1998 A
5752974 Rhee et al. May 1998 A
5762256 Mastri et al. Jun 1998 A
5766188 Igaki Jun 1998 A
5769892 Kingwell Jun 1998 A
5782396 Mastri et al. Jul 1998 A
5799857 Robertson et al. Sep 1998 A
5810855 Rayburn et al. Sep 1998 A
5814057 Oi et al. Sep 1998 A
5819350 Wang Oct 1998 A
5833695 Yoon Nov 1998 A
5843096 Igaki et al. Dec 1998 A
5874500 Rhee et al. Feb 1999 A
5895412 Tucker Apr 1999 A
5895415 Chow et al. Apr 1999 A
5902312 Frater et al. May 1999 A
5908427 McKean et al. Jun 1999 A
5915616 Viola et al. Jun 1999 A
5931847 Bittner et al. Aug 1999 A
5964774 McKean et al. Oct 1999 A
5997895 Narotam et al. Dec 1999 A
6019791 Wood Feb 2000 A
6030392 Dakov Feb 2000 A
6032849 Mastri et al. Mar 2000 A
6045560 McKean et al. Apr 2000 A
6063097 Oi et al. May 2000 A
6080169 Turtel Jun 2000 A
6093557 Pui et al. Jul 2000 A
6099551 Gabbay Aug 2000 A
6149667 Hovland et al. Nov 2000 A
6152943 Sawhney Nov 2000 A
6155265 Hammerslag Dec 2000 A
6156677 Brown Reed et al. Dec 2000 A
6165201 Sawhney et al. Dec 2000 A
6179862 Sawhney Jan 2001 B1
6210439 Firmin et al. Apr 2001 B1
6214020 Mulhauser et al. Apr 2001 B1
6241139 Milliman et al. Jun 2001 B1
6258107 Balazs et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6273897 Dalessandro et al. Aug 2001 B1
6280453 Kugel et al. Aug 2001 B1
6299631 Shalaby Oct 2001 B1
6309569 Farrar et al. Oct 2001 B1
6312457 DiMatteo et al. Nov 2001 B1
6312474 Francis et al. Nov 2001 B1
6325810 Hamilton et al. Dec 2001 B1
6399362 Pui et al. Jun 2002 B1
6436030 Rehil Aug 2002 B2
6454780 Wallace Sep 2002 B1
6461368 Fogarty et al. Oct 2002 B2
6500777 Wiseman et al. Dec 2002 B1
6503257 Grant et al. Jan 2003 B2
6514283 DiMatteo et al. Feb 2003 B2
6514534 Sawhney Feb 2003 B1
6517566 Hovland et al. Feb 2003 B1
6551356 Rousseau Apr 2003 B2
6566406 Pathak et al. May 2003 B1
6590095 Schleicher et al. Jul 2003 B1
6592597 Grant et al. Jul 2003 B2
6605294 Sawhney Aug 2003 B2
6627749 Kumar Sep 2003 B1
6638285 Gabbay Oct 2003 B2
6652594 Francis et al. Nov 2003 B2
6656193 Grant et al. Dec 2003 B2
6656200 Li et al. Dec 2003 B2
6669735 Pelissier Dec 2003 B1
6673093 Sawhney Jan 2004 B1
6677258 Carroll et al. Jan 2004 B2
6685714 Rousseau Feb 2004 B2
6702828 Whayne Mar 2004 B2
6703047 Sawhney et al. Mar 2004 B2
6704210 Myers Mar 2004 B1
6723114 Shalaby Apr 2004 B2
6726706 Dominguez Apr 2004 B2
6736823 Darois et al. May 2004 B2
6736854 Vadurro et al. May 2004 B2
6746458 Cloud Jun 2004 B1
6746869 Pui et al. Jun 2004 B2
6764720 Pui et al. Jul 2004 B2
6773458 Brauker et al. Aug 2004 B1
6818018 Sawhney Nov 2004 B1
6896684 Monassevitch et al. May 2005 B2
6927315 Heinecke et al. Aug 2005 B1
6939358 Palacios et al. Sep 2005 B2
6946196 Foss Sep 2005 B2
6953139 Milliman et al. Oct 2005 B2
6959851 Heinrich Nov 2005 B2
7009034 Pathak et al. Mar 2006 B2
7060087 DiMatteo et al. Jun 2006 B2
7087065 Ulmsten et al. Aug 2006 B2
7108701 Evens et al. Sep 2006 B2
7128253 Mastri et al. Oct 2006 B2
7128748 Mooradian et al. Oct 2006 B2
7134438 Makower et al. Nov 2006 B2
7141055 Abrams et al. Nov 2006 B2
7147138 Shelton, IV Dec 2006 B2
7160299 Baily Jan 2007 B2
7232449 Sharkawy et al. Jun 2007 B2
7241300 Sharkawy et al. Jul 2007 B2
7247338 Pui et al. Jul 2007 B2
7279322 Pui et al. Oct 2007 B2
7307031 Carroll et al. Dec 2007 B2
7311720 Mueller et al. Dec 2007 B2
7347850 Sawhney Mar 2008 B2
7377928 Zubik et al. May 2008 B2
7434717 Shelton, IV et al. Oct 2008 B2
7438209 Hess Oct 2008 B1
7455682 Viola Nov 2008 B2
7498063 Pui et al. Mar 2009 B2
7547312 Bauman et al. Jun 2009 B2
7559937 de la Torre et al. Jul 2009 B2
7571845 Viola Aug 2009 B2
7592418 Pathak et al. Sep 2009 B2
7594921 Browning Sep 2009 B2
7595392 Kumar et al. Sep 2009 B2
7604151 Hess et al. Oct 2009 B2
7611494 Campbell et al. Nov 2009 B2
7635073 Heinrich Dec 2009 B2
7649089 Kumar et al. Jan 2010 B2
7662801 Kumar et al. Feb 2010 B2
7665646 Prommersberger Feb 2010 B2
7666198 Suyker et al. Feb 2010 B2
7669747 Weisenburgh, II et al. Mar 2010 B2
7673783 Morgan Mar 2010 B2
7717313 Criscuolo et al. May 2010 B2
7722642 Williamson, IV et al. May 2010 B2
7744627 Orban, III et al. Jun 2010 B2
7776060 Mooradian et al. Aug 2010 B2
7793813 Bettuchi Sep 2010 B2
7799026 Schechter et al. Sep 2010 B2
7823592 Bettuchi et al. Nov 2010 B2
7824420 Eldridge et al. Nov 2010 B2
7845533 Marczyk et al. Dec 2010 B2
7845536 Viola Dec 2010 B2
7846149 Jankowski Dec 2010 B2
7892247 Conston et al. Feb 2011 B2
7909224 Prommersberger Mar 2011 B2
7909837 Crews et al. Mar 2011 B2
7938307 Bettuchi May 2011 B2
7942890 D'Agostino et al. May 2011 B2
7950561 Aranyi May 2011 B2
7951166 Orban, III et al. May 2011 B2
7951248 Fallis et al. May 2011 B1
7967179 Olson et al. Jun 2011 B2
7988027 Olson et al. Aug 2011 B2
8011550 Aranyi et al. Sep 2011 B2
8011555 Tarinelli et al. Sep 2011 B2
8016177 Bettuchi et al. Sep 2011 B2
8016178 Olson et al. Sep 2011 B2
8028883 Stopek Oct 2011 B2
8033483 Fortier et al. Oct 2011 B2
8038045 Bettuchi et al. Oct 2011 B2
8062330 Prommersberger et al. Nov 2011 B2
8062673 Figuly et al. Nov 2011 B2
8083119 Prommersberger Dec 2011 B2
8123766 Bauman et al. Feb 2012 B2
8123767 Bauman et al. Feb 2012 B2
8146791 Bettuchi et al. Apr 2012 B2
8152777 Campbell et al. Apr 2012 B2
8157149 Olson et al. Apr 2012 B2
8157151 Ingmanson et al. Apr 2012 B2
8167895 D'Agostino et al. May 2012 B2
8178746 Hildeberg et al. May 2012 B2
8192460 Orban, III et al. Jun 2012 B2
8201720 Hessler Jun 2012 B2
8210414 Bettuchi et al. Jul 2012 B2
8210453 Hull et al. Jul 2012 B2
8225799 Bettuchi Jul 2012 B2
8225981 Criscuolo et al. Jul 2012 B2
8231043 Tarinelli et al. Jul 2012 B2
8235273 Olson et al. Aug 2012 B2
8245901 Stopek Aug 2012 B2
8252339 Figuly et al. Aug 2012 B2
8252921 Vignon et al. Aug 2012 B2
8256654 Bettuchi et al. Sep 2012 B2
8257391 Orban, III et al. Sep 2012 B2
8276800 Bettuchi Oct 2012 B2
8286849 Bettuchi Oct 2012 B2
8292154 Marczyk Oct 2012 B2
8308042 Aranyi Nov 2012 B2
8308045 Bettuchi et al. Nov 2012 B2
8308046 Prommersberger Nov 2012 B2
8312885 Bettuchi et al. Nov 2012 B2
8313014 Bettuchi Nov 2012 B2
8348126 Olson et al. Jan 2013 B2
8348130 Shah et al. Jan 2013 B2
8365972 Aranyi et al. Feb 2013 B2
8367089 Wan et al. Feb 2013 B2
8371491 Huitema et al. Feb 2013 B2
8371492 Aranyi et al. Feb 2013 B2
8371493 Aranyi et al. Feb 2013 B2
8393514 Shelton, IV et al. Mar 2013 B2
8408440 Olson et al. Apr 2013 B2
8408480 Hull et al. Apr 2013 B2
8413869 Heinrich Apr 2013 B2
8413871 Racenet et al. Apr 2013 B2
8418909 Kostrzewski Apr 2013 B2
8424742 Bettuchi Apr 2013 B2
8453652 Stopek Jun 2013 B2
8453904 Eskaros et al. Jun 2013 B2
8453909 Olson et al. Jun 2013 B2
8453910 Bettuchi et al. Jun 2013 B2
8464925 Hull et al. Jun 2013 B2
8470360 McKay Jun 2013 B2
8474677 Woodard, Jr. et al. Jul 2013 B2
8479968 Hodgkinson et al. Jul 2013 B2
8485414 Criscuolo et al. Jul 2013 B2
8496683 Prommersberger et al. Jul 2013 B2
8511533 Viola et al. Aug 2013 B2
8512402 Marczyk et al. Aug 2013 B2
8518440 Blaskovich et al. Aug 2013 B2
8529600 Woodard, Jr. et al. Sep 2013 B2
8540131 Swayze Sep 2013 B2
8551138 Orban, III et al. Oct 2013 B2
8556918 Bauman et al. Oct 2013 B2
8561873 Ingmanson et al. Oct 2013 B2
8584920 Hodgkinson Nov 2013 B2
8590762 Hess et al. Nov 2013 B2
8616430 (Prommersberger) Stopek et al. Dec 2013 B2
8617132 Golzarian et al. Dec 2013 B2
8631989 Aranyi et al. Jan 2014 B2
8646674 Schulte et al. Feb 2014 B2
8668129 Olson Mar 2014 B2
8678263 Viola Mar 2014 B2
8684250 Bettuchi et al. Apr 2014 B2
8721703 Fowler May 2014 B2
8757466 Olson et al. Jun 2014 B2
8789737 Hodgkinson et al. Jul 2014 B2
8820606 Hodgkinson Sep 2014 B2
8870050 Hodgkinson Oct 2014 B2
8920444 Hiles et al. Dec 2014 B2
8939344 Olson et al. Jan 2015 B2
8967448 Carter et al. Mar 2015 B2
9005243 Stopek et al. Apr 2015 B2
9010606 Aranyi et al. Apr 2015 B2
9010608 Casasanta, Jr. et al. Apr 2015 B2
9010609 Carter et al. Apr 2015 B2
9010610 Hodgkinson Apr 2015 B2
9010612 Stevenson et al. Apr 2015 B2
9016543 (Prommersberger) Stopek et al. Apr 2015 B2
9016544 Hodgkinson et al. Apr 2015 B2
9044227 Shelton, IV et al. Jun 2015 B2
9055944 Hodgkinson et al. Jun 2015 B2
9084602 Gleiman Jul 2015 B2
9107665 Hodgkinson et al. Aug 2015 B2
9107667 Hodgkinson Aug 2015 B2
9113871 Milliman et al. Aug 2015 B2
9113873 Marczyk et al. Aug 2015 B2
9113885 Hodgkinson et al. Aug 2015 B2
9113893 Sorrentino et al. Aug 2015 B2
9161753 Prior Oct 2015 B2
9161757 Bettuchi Oct 2015 B2
9375259 Payne Jun 2016 B2
9895147 Shelton, IV Feb 2018 B2
10130359 Hess Nov 2018 B2
20020028243 Masters Mar 2002 A1
20020086990 Kumar et al. Jul 2002 A1
20020091397 Chen Jul 2002 A1
20030065345 Neadock Apr 2003 A1
20030078209 Schmidt Apr 2003 A1
20030083676 Wallace May 2003 A1
20030120284 Palacios et al. Jun 2003 A1
20030181927 Wallace Sep 2003 A1
20030183671 Mooradian et al. Oct 2003 A1
20030208231 Williamson et al. Nov 2003 A1
20040093029 Zubik et al. May 2004 A1
20040107006 Francis et al. Jun 2004 A1
20040254590 Hoffman et al. Dec 2004 A1
20040260315 Dell et al. Dec 2004 A1
20050002981 Lahtinen et al. Jan 2005 A1
20050021085 Abrams et al. Jan 2005 A1
20050059996 Bauman et al. Mar 2005 A1
20050059997 Bauman et al. Mar 2005 A1
20050070929 Dalessandro et al. Mar 2005 A1
20050118435 DeLucia et al. Jun 2005 A1
20050131225 Kumar et al. Jun 2005 A1
20050143756 Jankowski Jun 2005 A1
20050145671 Viola Jul 2005 A1
20050149073 Arani et al. Jul 2005 A1
20050154093 Kwon et al. Jul 2005 A1
20060004407 Hiles et al. Jan 2006 A1
20060008505 Brandon Jan 2006 A1
20060093672 Kumar et al. May 2006 A1
20060111738 Wenchell May 2006 A1
20060121266 Fandel et al. Jun 2006 A1
20060135992 Bettuchi et al. Jun 2006 A1
20060173470 Oray et al. Aug 2006 A1
20060178683 Shimoji et al. Aug 2006 A1
20060271104 Viola et al. Nov 2006 A1
20070026031 Bauman et al. Feb 2007 A1
20070034669 de la Torre et al. Feb 2007 A1
20070049953 Shimoji et al. Mar 2007 A2
20070054880 Saferstein et al. Mar 2007 A1
20070073340 Shelton et al. Mar 2007 A1
20070114262 Mastri et al. May 2007 A1
20070123839 Rousseau et al. May 2007 A1
20070179528 Soltz et al. Aug 2007 A1
20070203509 Bettuchi Aug 2007 A1
20070203510 Bettuchi Aug 2007 A1
20070213522 Harris et al. Sep 2007 A1
20070243227 Gertner Oct 2007 A1
20070246505 Pace-Floridia et al. Oct 2007 A1
20080029570 Shelton et al. Feb 2008 A1
20080082126 Murray et al. Apr 2008 A1
20080110959 Orban May 2008 A1
20080125812 Zubik et al. May 2008 A1
20080140115 Stopek Jun 2008 A1
20080161831 Bauman et al. Jul 2008 A1
20080161832 Bauman et al. Jul 2008 A1
20080164440 Maase et al. Jul 2008 A1
20080169327 Shelton et al. Jul 2008 A1
20080169328 Shelton Jul 2008 A1
20080169329 Shelton et al. Jul 2008 A1
20080169330 Shelton et al. Jul 2008 A1
20080169331 Shelton et al. Jul 2008 A1
20080169332 Shelton et al. Jul 2008 A1
20080169333 Shelton et al. Jul 2008 A1
20080200949 Hiles et al. Aug 2008 A1
20080220047 Sawhney et al. Sep 2008 A1
20080230583 Heinrich Sep 2008 A1
20080290134 Bettuchi et al. Nov 2008 A1
20080308608 Prommersberger Dec 2008 A1
20080314960 Marczyk et al. Dec 2008 A1
20090001121 Hess et al. Jan 2009 A1
20090001122 Prommersberger et al. Jan 2009 A1
20090001123 Morgan et al. Jan 2009 A1
20090001124 Hess et al. Jan 2009 A1
20090001125 Hess et al. Jan 2009 A1
20090001126 Hess et al. Jan 2009 A1
20090001128 Weisenburgh, II et al. Jan 2009 A1
20090001130 Hess et al. Jan 2009 A1
20090005808 Hess et al. Jan 2009 A1
20090030452 Bauman et al. Jan 2009 A1
20090043334 Bauman et al. Feb 2009 A1
20090076510 Bell et al. Mar 2009 A1
20090076528 Sgro Mar 2009 A1
20090078739 Viola Mar 2009 A1
20090095791 Eskaros et al. Apr 2009 A1
20090095792 Bettuchi Apr 2009 A1
20090120994 Murray May 2009 A1
20090134200 Tarinelli et al. May 2009 A1
20090206125 Huitema et al. Aug 2009 A1
20090206126 Huitema et al. Aug 2009 A1
20090206139 Hall et al. Aug 2009 A1
20090206141 Huitema et al. Aug 2009 A1
20090206142 Huitema et al. Aug 2009 A1
20090206143 Huitema et al. Aug 2009 A1
20090218384 Aranyi Sep 2009 A1
20090277944 Dalessandro et al. Nov 2009 A9
20090277947 Viola Nov 2009 A1
20090287230 D'Agostino et al. Nov 2009 A1
20100012704 Tarinelli Racenet et al. Jan 2010 A1
20100016888 Calabrese et al. Jan 2010 A1
20100065606 Stopek Mar 2010 A1
20100065607 Orban, III et al. Mar 2010 A1
20100072254 Aranyi et al. Mar 2010 A1
20100087840 Ebersole et al. Apr 2010 A1
20100147921 Olson Jun 2010 A1
20100147922 Olson Jun 2010 A1
20100147923 D'Agostino et al. Jun 2010 A1
20100203151 Hiraoka Aug 2010 A1
20100204641 Wenchell Aug 2010 A1
20100243707 Olson et al. Sep 2010 A1
20100243708 Aranyi et al. Sep 2010 A1
20100243711 Olson et al. Sep 2010 A1
20100249805 Olson et al. Sep 2010 A1
20100264195 Bettuchi Oct 2010 A1
20100282815 Bettuchi et al. Nov 2010 A1
20100331880 Stopek Dec 2010 A1
20110024476 Bettuchi et al. Feb 2011 A1
20110024481 Bettuchi et al. Feb 2011 A1
20110036894 Bettuchi Feb 2011 A1
20110042442 Viola et al. Feb 2011 A1
20110046650 Bettuchi Feb 2011 A1
20110057016 Bettuchi Mar 2011 A1
20110087279 Shah et al. Apr 2011 A1
20110089375 Chan et al. Apr 2011 A1
20110215132 Aranyi et al. Sep 2011 A1
20110278346 Hull Nov 2011 A1
20110293690 Griffin et al. Dec 2011 A1
20120018487 Bettuchi et al. Jan 2012 A1
20120074199 Olson et al. Mar 2012 A1
20120080336 Shelton, IV et al. Apr 2012 A1
20120083723 Vitaris et al. Apr 2012 A1
20120150221 Viola Jun 2012 A1
20120187179 Gleiman Jul 2012 A1
20120197272 Oray et al. Aug 2012 A1
20120241492 Shelton, IV Sep 2012 A1
20120241499 Baxter, III et al. Sep 2012 A1
20120273547 Hodgkinson et al. Nov 2012 A1
20130032626 Smith et al. Feb 2013 A1
20130037596 Bear et al. Feb 2013 A1
20130062391 Boudreaux Mar 2013 A1
20130105548 Hodgkinson et al. May 2013 A1
20130105553 (Tarinelli) Racenet et al. May 2013 A1
20130112732 Aranyi et al. May 2013 A1
20130112733 Aranyi et al. May 2013 A1
20130146641 Shelton, IV et al. Jun 2013 A1
20130153635 Hodgkinson Jun 2013 A1
20130153636 Shelton, IV et al. Jun 2013 A1
20130153638 Carter et al. Jun 2013 A1
20130153639 Hodgkinson et al. Jun 2013 A1
20130153640 Hodgkinson Jun 2013 A1
20130153641 Shelton, IV et al. Jun 2013 A1
20130161374 Swayze Jun 2013 A1
20130193186 (Tarinelli) Racenet et al. Aug 2013 A1
20130193192 Casasanta, Jr. et al. Aug 2013 A1
20130209659 Racenet et al. Aug 2013 A1
20130240600 Bettuchi Sep 2013 A1
20130240601 Bettuchi et al. Sep 2013 A1
20130240602 Stopek Sep 2013 A1
20130256380 Schmid et al. Oct 2013 A1
20130277411 Hodgkinson et al. Oct 2013 A1
20130306707 Viola et al. Nov 2013 A1
20130310873 Stopek (nee Prommersberger) et al. Nov 2013 A1
20130327807 Olson et al. Dec 2013 A1
20140012317 Orban et al. Jan 2014 A1
20140021242 Hodgkinson et al. Jan 2014 A1
20140027490 Marczyk et al. Jan 2014 A1
20140034704 Ingmanson et al. Feb 2014 A1
20140048580 Merchant et al. Feb 2014 A1
20140061280 Ingmanson et al. Mar 2014 A1
20140097224 Prior Apr 2014 A1
20140131418 Kostrzewski May 2014 A1
20140131419 Bettuchi May 2014 A1
20140138423 Whitfield et al. May 2014 A1
20140151431 Hodgkinson et al. Jun 2014 A1
20140155916 Hodgkinson et al. Jun 2014 A1
20140158742 Stopek (nee Prommersberger) et al. Jun 2014 A1
20140166721 Stevenson et al. Jun 2014 A1
20140197224 Penna Jul 2014 A1
20140203061 Hodgkinson Jul 2014 A1
20140217147 Milliman Aug 2014 A1
20140217148 Penna Aug 2014 A1
20140239046 Milliman Aug 2014 A1
20140239047 Hodgkinson et al. Aug 2014 A1
20140252062 Mozdzierz Sep 2014 A1
20150001276 Hodgkinson et al. Jan 2015 A1
20150041347 Hodgkinson Feb 2015 A1
20150097018 Hodgkinson Apr 2015 A1
20150115014 Matonick Apr 2015 A1
20150115015 Prescott et al. Apr 2015 A1
20150122872 Olson et al. May 2015 A1
20150164503 Stevenson et al. Jun 2015 A1
20150164506 Carter et al. Jun 2015 A1
20150164507 Carter et al. Jun 2015 A1
20150196297 (Prommersberger) Stopek et al. Jul 2015 A1
20150209033 Hodgkinson Jul 2015 A1
20150209045 Hodgkinson et al. Jul 2015 A1
20150209048 Carter et al. Jul 2015 A1
20160206864 Matonick Jul 2016 A1
20160206865 Matonick Jul 2016 A1
Foreign Referenced Citations (11)
Number Date Country
19924311 Nov 2000 DE
0 327 022 Aug 1989 EP
0 594 148 Apr 1994 EP
H06327684 Nov 1994 JP
2000-166933 Jun 2000 JP
2002-202213 Jul 2002 JP
2007-124166 May 2007 JP
9005489 May 1990 WO
9516221 Jun 1995 WO
2006044799 Apr 2006 WO
2010075298 Jul 2010 WO
Non-Patent Literature Citations (5)
Entry
International Search Report dated Jul. 25, 2016, issued in PCT/US2016/026334.
Extended European Search Report dated Jan. 15, 2019 issued in corresponding EP Appln. No. 16777239.1.
Australian Office Action issued in Application No. 2016246716 dated Nov. 21, 2019.
Australian Office Action issued in Application No. 2016246716, dated Apr. 14, 2020.
Extended European Search Report issued in EP Application No. EP16777239.1, dated Jan. 15, 2019.
Related Publications (1)
Number Date Country
20160296227 A1 Oct 2016 US
Provisional Applications (2)
Number Date Country
62148827 Apr 2015 US
62145930 Apr 2015 US